CRKL silencing inhibits melanoma growth and enhances its chemotherapy sensitivity through the PI3K/AKT and NLRP3/GSDMD pathways
Biochemical Pharmacology · 2025-05 · 235 · 116840
DOI: 10.1016/j.bcp.2025.116840 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2025-05. Verfasst von Jiashe Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai 200443, China. Hauptthemen laut MEDLINE: Melanoma, Proto-Oncogene Proteins c-akt, NLR Family, Pyrin Domain-Containing 3 Protein, Adaptor Proteins, Signal Transducing. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: Tongji University, Shanghai Municipal Natural Science Foundation.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Great advances have been made in malignant melanoma treatments, whereas drug resistance still limits many drug applications. CRKL has been reported to be overexpressed in various tumors and showed poor prognosis. However, its specific function and mechanism in melanoma remain unclear. In the present study, we investigated the expression of CRKL and its clinical association by bioinformatics and clinical analysis, and then performed a series of in vitro and in vivo experiments to demonstrate its function and mechanism. Results showed that CRKL increased during melanoma progression and was strongly associated with poor prognosis. CRKL silencing effectively inhibited melanoma cell growth and invasion via ERK/MMP9 and PI3K/AKT signaling pathways both in vitro and in vivo. Moreover, CRKL silencing induced pyroptosis in melanoma cells by upregulating the levels of pyroptosis-associated proteins, such as NLRP3, cleaved Caspase-1, and GSDMD-N. Importantly, our study demonstrated that interfering with CRKL expression enhanced the chemotherapy sensitivity of melanoma cells to cisplatin by regulating PI3K/AKT and NLRP3/GSDMD signaling pathways. In conclusion, our study uncovers a novel molecular mechanism by which CRKL functions in melanoma and highlights potential therapeutic strategies for improving chemotherapy sensitivity in melanoma patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai 200443, China.
- Department of Pathology, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai 200443, China. Electronic address: xiaoxiangxu@tongji.edu.cn.
- Department of Pathology, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai 200443, China. Electronic address: 1500156@tongji.edu.cn.
Förderung
- Tongji University
- Shanghai Municipal Natural Science Foundation
Zitieren
APA
Chen, J., Xu, M., Wu, F., Wu, N., Li, J., Xie, Y., Wang, R., Xi, N., Zhu, Y., Xu, X., & Liu, Y. (2025). CRKL silencing inhibits melanoma growth and enhances its chemotherapy sensitivity through the PI3K/AKT and NLRP3/GSDMD pathways. Biochemical Pharmacology, 235, 116840. https://doi.org/10.1016/j.bcp.2025.116840
Vancouver
Chen J, Xu M, Wu F, Wu N, Li J, Xie Y, et al. CRKL silencing inhibits melanoma growth and enhances its chemotherapy sensitivity through the PI3K/AKT and NLRP3/GSDMD pathways. Biochemical Pharmacology. 2025;235:116840. doi:10.1016/j.bcp.2025.116840
BibTeX
@article{Chen2025,
author = {Chen, Jiashe and Xu, Mingyuan and Wu, Fei and Wu, Nanhui and Li, Jie and Xie, Yongyi and Wang, Ruoqi and Xi, Ningyuan and Zhu, Yueyi and Xu, Xiaoxiang and Liu, Yeqiang},
title = {CRKL silencing inhibits melanoma growth and enhances its chemotherapy sensitivity through the PI3K/AKT and NLRP3/GSDMD pathways},
journal = {Biochemical Pharmacology},
year = {2025},
volume = {235},
pages = {116840},
doi = {10.1016/j.bcp.2025.116840}
}
EUVIMED